Corbus Pharmaceuticals (CRBP)
NASDAQ:CRBP
Top Page
Corbus Pharmaceuticals
(NASDAQ:CRBP)
Select Model
Select Model
Rating:57Neutral
Price Target:
$8.50
▼(-2.41% Downside)
Action:ReiteratedDate:03/10/26
The score is driven by a stronger balance sheet and positive corporate updates (including extended runway into 2028), partly offset by a pre-revenue model with widening losses and increasing cash burn. Technicals add modest support due to improving near-term momentum, while negative earnings (negative P/E) weighs on valuation.
Positive Factors
Strong balance sheet
Return to positive equity and minimal debt gives Corbus durable financial flexibility to fund multi-year clinical programs. Low leverage reduces near-term refinancing risk and supports R&D spend without immediate reliance on dilutive financing, preserving strategic optionality over 2–6 months.
Negative Factors
Pre-revenue model
Corbus remains a pre-commercial biotech with no meaningful product revenues, meaning long-term value depends entirely on clinical success and external financing. Lack of operating revenue limits margin sustainability and increases exposure to clinical and regulatory outcomes over the next 2–6 months.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet
Return to positive equity and minimal debt gives Corbus durable financial flexibility to fund multi-year clinical programs. Low leverage reduces near-term refinancing risk and supports R&D spend without immediate reliance on dilutive financing, preserving strategic optionality over 2–6 months.
Read all positive factors
Corbus Pharmaceuticals (CRBP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$154.48M
Dividend YieldN/A
Average Volume (3M)503.64K
Price to Earnings (P/E)―
Beta (1Y)1.56
Revenue GrowthN/A
EPS Growth-17.43%
CountryUS
Employees28
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.25
Shares Outstanding17,736,464
10 Day Avg. Volume744,820
30 Day Avg. Volume503,638
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.73
Price to Sales (P/S)0.00
P/FCF Ratio-1.68
Enterprise Value/Market Cap0.53
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-5.21
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$41.27Price Target Upside373.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-4.58
Revenue Forecast (FY)$5.33M
Corbus Pharmaceuticals Business Overview & Revenue Model
Company Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor ...
How the Company Makes Money
null...
Corbus Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
34
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 881.71K |
| Gross Profit | -233.00K | -600.00K | 0.00 | -1.49M | -757.53K |
| EBITDA | -85.08M | -37.74M | -40.10M | -38.73M | -54.35M |
| Net Income | -78.54M | -40.21M | -44.60M | -55.83M | -45.55M |
Balance Sheet | |||||
| Total Assets | 168.19M | 155.88M | 28.27M | 66.31M | 107.73M |
| Cash, Cash Equivalents and Short-Term Investments | 28.49M | 149.06M | 20.91M | 59.20M | 97.65M |
| Total Debt | 1.63M | 3.24M | 20.89M | 25.09M | 26.59M |
| Total Liabilities | 20.69M | 13.45M | 35.18M | 33.32M | 38.62M |
| Stockholders Equity | 147.50M | 142.43M | -6.91M | 32.99M | 69.11M |
Cash Flow | |||||
| Free Cash Flow | -64.50M | -41.79M | -36.10M | -37.56M | -48.24M |
| Operating Cash Flow | -64.49M | -41.79M | -36.10M | -37.54M | -48.18M |
| Investing Cash Flow | -1.64M | -121.31M | 35.64M | 30.07M | -73.42M |
| Financing Cash Flow | 77.43M | 166.58M | -2.82M | -533.62K | 60.82M |
Corbus Pharmaceuticals Technical Analysis
Negative
8.71
Price Trends
8.45
Positive
9.13
Negative
10.01
Negative
Market Momentum
0.09
Positive
49.94
Neutral
34.16
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRBP, the sentiment is Negative. The current price of 8.71 is below the 20-day moving average (MA) of 8.93, above the 50-day MA of 8.45, and below the 200-day MA of 10.01, indicating a neutral trend. The MACD of 0.09 indicates Positive momentum. The RSI at 49.94 is Neutral, neither overbought nor oversold. The STOCH value of 34.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRBP.
Corbus Pharmaceuticals Risk Analysis
Corbus Pharmaceuticals disclosed 51 risk factors in its most recent earnings report. Corbus Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Corbus Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $154.48M | -1.38 | -65.76% | ― | ― | -17.43% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $95.44M | 4.86 | -209.00% | ― | ― | 40.22% | |
49 Neutral | $56.25M | -1.41 | -71.28% | ― | -10.03% | 11.06% | |
46 Neutral | $40.65M | -2.19 | -49.42% | ― | ― | -9.42% |
* Healthcare Sector Average
CRBP
Corbus Pharmaceuticals
8.71
3.40
64.03%
ATOS
Atossa Therapeutics
4.72
-5.37
-53.23%
BMEA
Biomea Fusion
1.32
-0.81
-38.03%
TCRX
TScan Therapeutics
0.99
-0.39
-28.41%
Corbus Pharmaceuticals Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Corbus Pharmaceuticals Highlights 2025 Results and Pipeline Progress
Positive
Mar 9, 2026
On March 9, 2026, Corbus Pharmaceuticals reported fourth-quarter and full-year 2025 results, highlighting strong clinical progress across its pipeline and a bolstered balance sheet. In oncology, Q4 2025 Phase 1/2 data for CRB-701 in head and neck ...
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
Corbus Highlights Diversified Oncology and Metabolic Pipeline Outlook
Positive
Feb 25, 2026
Corbus Pharmaceuticals presented an updated corporate overview dated February 25, 2026, highlighting a diversified pipeline led by CRB-701, a next-generation Nectin-4–targeting ADC designed for longer half-life, reduced free MMAE exposure, f...
Business Operations and StrategyProduct-Related Announcements
Corbus Updates Corporate Outlook, Highlights Diversified 2026 Pipeline
Positive
Jan 12, 2026
On January 12, 2026, Corbus Pharmaceuticals updated its corporate presentation to highlight a diversified pipeline and key clinical milestones expected in 2026, underpinned by $173 million in cash, cash equivalents and investments as of November 3...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.